Lung Cancer Diagnostic And Screening Market Trends Are Creating New Opportunities For Industry Leaders
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Lung Cancer Diagnostic And Screening Market Revenue Growth Supported By A CAGR Of 4.03% Through 2030
The market dedicated to the diagnosis and screening of lung cancer has experienced considerable expansion lately. Projections indicate a rise from $2.56 billion in 202
The market for lung cancer diagnostics and screening is poised for substantial expansion over the coming years, with projections indicating a rise to $4.04 billion by 2030, driven by a compound annual growth rate of 9.6%. This anticipated growth trajectory is fueled by several key factors, including the broadening reach of nationwide lung cancer screening programs, a greater acceptance of low-dose CT screening technologies, an escalating demand for both biomarker and blood-based testing solutions, increased financial commitments within the healthcare sector towards oncology diagnostics, and enhanced accessibility to diagnostic imaging facilities. Furthermore, prominent developments anticipated during this forecast period encompass a rise in the implementation of early lung cancer screening initiatives, increased utilization of sophisticated imaging and biomarker assays, a concentrated effort on screening high-risk demographic groups, the further development and deployment of non-invasive diagnostic methods, and a growing trend toward the combined use of various diagnostic approaches.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12043&type=smp
Lung Cancer Diagnostic And Screening Market Growth Drivers And Industry Catalysts
The accelerating incidence of lung cancer is poised to be a significant catalyst for the expansion of the lung cancer diagnostic and screening market. Lung cancer, characterized by the uncontrolled multiplication of aberrant cells within the lung tissue, manifests with distressing symptoms like persistent coughing, chest discomfort, and labored breathing. Detection and screening methods play a crucial role in the early identification of this condition, employing diverse diagnostic procedures such as incisional biopsies and bronchoscopies. To illustrate, data from January 2023, as reported by the American Cancer Society, a governmental entity in the U.S., indicated an estimated 238,340 new lung cancer diagnoses across the United States, comprising 117,550 males and 120,790 females. Additionally, this report detailed approximately 127,070 fatalities attributed to lung cancer, with 67,160 deaths occurring among men and 59,910 among women. Consequently, the escalating occurrence of lung cancer is a primary driver fueling the growth trajectory of the market dedicated to its diagnosis and screening.
Lung Cancer Diagnostic And Screening Market Segment Landscape: Which Areas Lead Market Development?
The lung cancer diagnostic and screening market covered in this report is segmented –
1) By Product: Instruments, Consumables And Accessories
2) By Test: Biomarkers Tests, Imaging Test, Biopsy, Blood Test, Other Tests
3) By Cancer Type: Non-Small Cell Lung Cancer, Small Cell Lung Cancer
4) By End User: Hospital, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, Other End-Users
Subsegments:
1) By Instruments: Imaging Devices, Biopsy Devices, Bronchoscopy Systems
2) By Consumables And Accessories: Biopsy Needles, Reagents And Assays, Imaging Contrast Agents, Sample Collection Kits
#Lung Cancer Diagnostic And Screening Market Trends Influencing Long-Term Demand
Several key players within the lung cancer diagnostic and screening sector are concentrating their efforts on pioneering a blood-based testing solution powered by machine learning technologies, specifically whole-genome machine learning, with the overarching goals of enhancing accessibility and convenience in lung cancer screening and securing a stronger market position. The concept of whole-genome machine learning involves the implementation of sophisticated algorithms to scrutinize and interpret the complete spectrum of an organism’s genetic data, covering its entire genome. As an illustrative example, in the month of October in 2023, DELFI Diagnostics Inc., a company based in the United States and known for its work on accessible blood tests, introduced FirstLook Lung. This groundbreaking blood test leverages whole-genome machine learning to examine fragments of cell-free DNA, thereby significantly improving lung cancer screening with an impressive negative predictive value of 99.7%. Developed with the intention of integration into standard blood work procedures, this test is capable of detecting individuals who may have lung cancer, including those in the initial stages of the disease. By aiming to overcome the challenge of low participation rates in low-dose computed tomography (LDCT) screening, this innovative test seeks to contribute positively to the overall health of the population.
Lung Cancer Diagnostic And Screening Market Industry Leaders And Market Competition
Major companies operating in the lung cancer diagnostic and screening market are Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Danaher Corporation, Siemens Healthcare GmbH, FUJIFILM Corporation, Koninklijke Philips N.V., GE Healthcare Bio Sciences AB, Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., Qiagen Inc., Myriad Genetic Laboratories Inc., NeoGenomics Laboratories Inc., Canon Medical Systems Corporation, Oncimmune Holdings Plc, Riverain Technologies LLC, VisionGate, Foundation Medicine Inc., Biodesix, OncoCyte, Broncus Medical Inc.
Access The Complete Lung Cancer Diagnostic And Screening Market Report:
Lung Cancer Diagnostic And Screening Market Global Footprint: Which Region Holds Market Leadership?
North America was the largest region in the lung cancer diagnostic and screening market in 2025. The regions covered in the lung cancer diagnostic and screening market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
